Prognostic Performance of a Genome-Wide Methylome Enrichment Platform in Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Circulating tumor DNA (ctDNA) can be utilized to identify the presence of cancer as well as minimal residual disease (MRD). Quantification of ctDNA can be a useful cancer management tool to assess prognosis. Here we evaluate the feasibility of using a tumor-na ïve genome-wide methylome enrichment platform to quantify ctDNA in plasma and predict recurrence in early-stage non-small cell lung cancer (NSCLC).

Source: International Journal of Radiation Oncology * Biology * Physics - December 3, 2023 Category: Radiology Authors: G. Liu, J. Zhang, Y. Wang, J. Burgener, O. Hall, S.Y. Shen, M. Pienkowski, S.H. Huang, E. Sosa, A. Polio, S.B. Goldberg, P. Mazzone, S. Bratman, A. Licon, K. Brown, B. Allen, A.R. Hartman, D.D. De Carvalho, B. Park Tags: 3 Source Type: research